title: [Locoregional therapy for liver metastases of colorectal cancer].
abstract: The role of biological response modifiers (BRM) in locoregional therapy for liver metastases of colorectal cancer was studied clinically and experimentally. Seven patients with numerous metastases to both lobes of liver were given intraarterial administration of BRM in combination with anticancer drugs. A partial response was observed in 1 patient. The response rate was 14.3%. Alternatively, intraarterial administration of both OK-432 and IL-2 into the rabbit with liver metastases of VX-2 tumors could bring about the infiltration of cytotoxic T lymphocytes around the tumors, followed by a significant decrease of the metastatic nodules. In addition, the same anti-tumor effect was observed when PSK was administered intraperitoneally into the BALB/c mouse with liver metastases of colon 26 tumors. Moreover, the therapeutic effect of water in oil type emulsion encapsulating both OK-432 and IL-2 was greater than that of the solution of BRM in BALB/c mouse with liver metastases of colon 26 tumors. These results indicated that BRM could be one of the promising agents in locoregional therapy against liver metastases of colorectal cancer.
authors.affiliation: 2nd Dept. of Surgery, Gifu University School of Medicine.
authors.forename: Y
authors.initials: Y
authors.lastname: Sugiyama
authors.forename: S
authors.initials: S
authors.lastname: Saji
authors.forename: K
authors.initials: K
authors.lastname: Miya
authors.forename: D
authors.initials: D
authors.lastname: Fukada
authors.forename: T
authors.initials: T
authors.lastname: Umemoto
authors.forename: K
authors.initials: K
authors.lastname: Kunieda
authors.forename: H
authors.initials: H
authors.lastname: Takao
authors.forename: M
authors.initials: M
authors.lastname: Kato
authors.forename: M
authors.initials: M
authors.lastname: Kawai
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D015179:Colorectal Neoplasms / Q000473:pathology*; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D007376:Interleukin-2 / Q000008:administration & dosage*; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy*; D008114:Liver Neoplasms, Experimental / Q000556:secondary / Q000628:therapy; D008297:Male; D051379:Mice; D008875:Middle Aged; D010844:Picibanil / Q000008:administration & dosage*; D011817:Rabbits
chemical_list: D007376:Interleukin-2; D010844:Picibanil; D004317:Doxorubicin; C027260:pirarubicin; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil